More serious but rare risks include pancreatitis, gallbladder disease, and potential dehydration leading to acute kidney injury with severe gastrointestinal effects
Recent US observational cohort studies and pharmacovigilance databases have not identified a clear signal of IBD exacerbation with GLP-1 medications, though systematic studies are limited by confounding factors and selection bias
Archived from the original on February 7, 2025

GLP-3 Lets break down the key differences in a clear, comparative format: Primary Location of Action GLP-1: Pancreas, brain, stomach, cardiovascular system GLP-2: Intestinal tract, gut epithelium GLP-3: Unknown/under investigation Main Functions GLP-1: Regulates blood sugar Suppresses appetite Promotes weight loss Slows gastric emptying Protects cardiovascular system GLP-2: Promotes intestinal growth Enhances nutrient absorption Repairs gut lining Reduces inflammation Strengthens gut barrier GLP-3: Functions not well established Potentially metabolic or intestinal Requires more research Clinical Applications GLP-1: Type 2 diabetes treatment Obesity and weight management Cardiovascular disease prevention Potential neuroprotection GLP-2: Short bowel syndrome Inflammatory bowel disease (experimental) Intestinal injury recovery Malabsorption disorders GLP-3: No established clinical applications Currently research-only Half-Life GLP-1: Very short (2 minutes for natural form

Cagrilintide acts through the amylin system agonism at amylin/calcitonin receptors a pathway entirely separate from the incretins
This leads to stronger, healthier, and younger looking skin